Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma.

Date publication

juillet 2022

Journal

Frontiers in oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe , Dr VIENOT Angélique , Dr KIM Stephano , Dr BOUSTANI Jihane

Tous les auteurs :
Grave A, Blanc J, De Bari B, Pernot M, Boulbair F, Noirclerc M, Vienot A, Kim S, Borg C, Boustani J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35936677

Résumé

The incidence of metastatic squamous cell carcinoma of the anus (SCCA) is increasing. Even if systemic docetaxel, cisplatin, and 5-Fluorouracil (DCF) provide a high rate of long-term remission, the role of pelvic chemoradiation (CRT) is unknown in this setting. We reported the safety and efficacy of local CRT in patients with synchronous metastatic SCCA who achieved objective response after upfront DCF.

Mots clés

long-term control, metastatic setting, pelvic chemoradiotherapy, squamous cell carcinoma of the anus (SCCA), upfront chemotherapy

Référence

Front Oncol. 2022 07 22;12:918271